These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 26861454)

  • 1. Olfactory Receptor Family 7 Subfamily C Member 1 Is a Novel Marker of Colon Cancer-Initiating Cells and Is a Potent Target of Immunotherapy.
    Morita R; Hirohashi Y; Torigoe T; Ito-Inoda S; Takahashi A; Mariya T; Asanuma H; Tamura Y; Tsukahara T; Kanaseki T; Kubo T; Kutomi G; Mizuguchi T; Terui T; Ishitani K; Hashino S; Kondo T; Minagawa N; Takahashi N; Taketomi A; Todo S; Asaka M; Sato N
    Clin Cancer Res; 2016 Jul; 22(13):3298-309. PubMed ID: 26861454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heat shock protein DNAJB8 is a novel target for immunotherapy of colon cancer-initiating cells.
    Morita R; Nishizawa S; Torigoe T; Takahashi A; Tamura Y; Tsukahara T; Kanaseki T; Sokolovskaya A; Kochin V; Kondo T; Hashino S; Asaka M; Hara I; Hirohashi Y; Sato N
    Cancer Sci; 2014 Apr; 105(4):389-95. PubMed ID: 24450541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class I molecules.
    Tallerico R; Todaro M; Di Franco S; Maccalli C; Garofalo C; Sottile R; Palmieri C; Tirinato L; Pangigadde PN; La Rocca R; Mandelboim O; Stassi G; Di Fabrizio E; Parmiani G; Moretta A; Dieli F; Kärre K; Carbone E
    J Immunol; 2013 Mar; 190(5):2381-90. PubMed ID: 23345327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring olfactory receptor family 7 subfamily C member 1 as a novel oral cancer stem cell target for immunotherapy.
    Miyamoto S; Hirohashi Y; Morita R; Miyazaki A; Ogi K; Kanaseki T; Ide K; Shirakawa J; Tsukahara T; Murai A; Sasaya T; Koike K; Kina S; Kawano T; Goto T; Ntege EH; Shimizu Y; Torigoe T
    Cancer Sci; 2023 Sep; 114(9):3496-3508. PubMed ID: 37344992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA methyltransferase 1 is essential for initiation of the colon cancers.
    Morita R; Hirohashi Y; Suzuki H; Takahashi A; Tamura Y; Kanaseki T; Asanuma H; Inoda S; Kondo T; Hashino S; Hasegawa T; Tokino T; Toyota M; Asaka M; Torigoe T; Sato N
    Exp Mol Pathol; 2013 Apr; 94(2):322-9. PubMed ID: 23064049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ectopically expressed variant form of sperm mitochondria-associated cysteine-rich protein augments tumorigenicity of the stem cell population of lung adenocarcinoma cells.
    Takahashi A; Hirohashi Y; Torigoe T; Tamura Y; Tsukahara T; Kanaseki T; Kochin V; Saijo H; Kubo T; Nakatsugawa M; Asanuma H; Hasegawa T; Kondo T; Sato N
    PLoS One; 2013; 8(11):e69095. PubMed ID: 24244262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells.
    Morrison BJ; Steel JC; Morris JC
    BMC Cancer; 2018 Apr; 18(1):469. PubMed ID: 29699516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An adoptive T cell immunotherapy targeting cancer stem cells in a colon cancer model.
    Gao XY; Wang XL
    J BUON; 2015; 20(6):1456-63. PubMed ID: 26854441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is a novel target of lung cancer stem-like cell immunotherapy.
    Horibe R; Hirohashi Y; Asano T; Mariya T; Suzuki T; Takaya A; Saijo H; Shionoya Y; Kubo T; Nakatsugawa M; Kanaseki T; Tsukahara T; Watanabe K; Atsuyama E; Toji S; Hirano H; Hasegawa T; Takahashi H; Sato N; Torigoe T
    PLoS One; 2017; 12(3):e0171460. PubMed ID: 28248963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxic T lymphocytes efficiently recognize human colon cancer stem-like cells.
    Inoda S; Hirohashi Y; Torigoe T; Morita R; Takahashi A; Asanuma H; Nakatsugawa M; Nishizawa S; Tamura Y; Tsuruma T; Terui T; Kondo T; Ishitani K; Hasegawa T; Hirata K; Sato N
    Am J Pathol; 2011 Apr; 178(4):1805-13. PubMed ID: 21435460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment and Analysis of Cancer Stem-Like and Non-Cancer Stem-Like Clone Cells from the Human Colon Cancer Cell Line SW480.
    Takaya A; Hirohashi Y; Murai A; Morita R; Saijo H; Yamamoto E; Kubo T; Nakatsugawa M; Kanaseki T; Tsukahara T; Tamura Y; Takemasa I; Kondo T; Sato N; Torigoe T
    PLoS One; 2016; 11(7):e0158903. PubMed ID: 27415781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is involved in cervical cancer stemness and can be a target of immunotherapy.
    Asano T; Hirohashi Y; Torigoe T; Mariya T; Horibe R; Kuroda T; Tabuchi Y; Saijo H; Yasuda K; Mizuuchi M; Takahashi A; Asanuma H; Hasegawa T; Saito T; Sato N
    Oncotarget; 2016 Mar; 7(10):11223-37. PubMed ID: 26849232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and functional analysis of variants of a cancer/testis antigen LEMD1 in colorectal cancer stem-like cells.
    Takeda R; Hirohashi Y; Shen M; Wang L; Ogawa T; Murai A; Yamamoto E; Kubo T; Nakatsugawa M; Kanaseki T; Tsukahara T; Nishidate T; Okita K; Kutomi G; Sato N; Takemasa I; Torigoe T
    Biochem Biophys Res Commun; 2017 Apr; 485(3):651-657. PubMed ID: 28219643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GRIK2 has a role in the maintenance of urothelial carcinoma stem-like cells, and its expression is associated with poorer prognosis.
    Inoue R; Hirohashi Y; Kitamura H; Nishida S; Murai A; Takaya A; Yamamoto E; Matsuki M; Tanaka T; Kubo T; Nakatsugawa M; Kanaseki T; Tsukahara T; Sato N; Masumori N; Torigoe T
    Oncotarget; 2017 Apr; 8(17):28826-28839. PubMed ID: 28418868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers.
    Imai K; Hirata S; Irie A; Senju S; Ikuta Y; Yokomine K; Harao M; Inoue M; Tsunoda T; Nakatsuru S; Nakagawa H; Nakamura Y; Baba H; Nishimura Y
    Clin Cancer Res; 2008 Oct; 14(20):6487-95. PubMed ID: 18927288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GRIK2 is a target for bladder cancer stem-like cell-targeting immunotherapy.
    Miyata H; Hirohashi Y; Yamada S; Yanagawa J; Murai A; Hashimoto S; Tokita S; Hori K; Abe T; Kubo T; Tsukahara T; Kanaseki T; Shinohara N; Torigoe T
    Cancer Immunol Immunother; 2022 Apr; 71(4):795-806. PubMed ID: 34405274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Annexin A3 as a potential target for immunotherapy of liver cancer stem-like cells.
    Pan QZ; Pan K; Wang QJ; Weng DS; Zhao JJ; Zheng HX; Zhang XF; Jiang SS; Lv L; Tang Y; Li YQ; He J; Liu Q; Chen CL; Zhang HX; Xia JC
    Stem Cells; 2015 Feb; 33(2):354-66. PubMed ID: 25267273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy sensitizes colon cancer initiating cells to Vγ9Vδ2 T cell-mediated cytotoxicity.
    Todaro M; Orlando V; Cicero G; Caccamo N; Meraviglia S; Stassi G; Dieli F
    PLoS One; 2013; 8(6):e65145. PubMed ID: 23762301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOXM1-Induced PRX3 Regulates Stemness and Survival of Colon Cancer Cells via Maintenance of Mitochondrial Function.
    Song IS; Jeong YJ; Jeong SH; Heo HJ; Kim HK; Bae KB; Park YH; Kim SU; Kim JM; Kim N; Ko KS; Rhee BD; Han J
    Gastroenterology; 2015 Oct; 149(4):1006-16.e9. PubMed ID: 26091938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficiency of G2/M-related tumor-associated antigen-targeting cancer immunotherapy depends on antigen expression in the cancer stem-like population.
    Mori T; Nishizawa S; Hirohashi Y; Torigoe T; Tamura Y; Takahashi A; Kochin V; Fujii R; Kondo T; Greene MI; Hara I; Sato N
    Exp Mol Pathol; 2012 Feb; 92(1):27-32. PubMed ID: 22001602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.